Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether BNP7787 is effective in preventing or
reducing neurotoxicity (nerve damage) caused by paclitaxel (Taxol®).
Phase:
Phase 3
Details
Lead Sponsor:
BioNumerik Pharmaceuticals, Inc.
Collaborator:
Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of March 26, 2019.